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Abstract In this study we compared the efficacy of virtual reality exposure combined with 
cognitive-behavioral therapy (VRET) to that of traditional cognitive-behavioral therapy (CBT) 
alone in reducing phobic symptoms in a sample of patients with long-term agoraphobia. The 
study was a between-subject design with three experimental conditions (VRET group, N = 30; 
CBT group, N = 30; and medication only group, N = 20) and repeated measures (pre-treatment, 
post-treatment, and six-month follow-up). All patients were receiving antidepressant 
medication. Results showed that all therapies were statistically effective both at post-treatment 
and six-month follow-up. The VRET group showed clinical improvement in most variables 
measured at follow-up. The CBT group showed the highest dropout rates. These results are 
discussed pointing out that VRET probably serves as an intermediate procedure for an efficient 
exposure to phobic stimuli. Besides describing the advantages of VRET for the treatment of 
agoraphobia symptoms in cost-benefit terms, the study also considered issues related to higher 
treatment adherence and motivation.
© 2013 Asociación Española de Psicología Conductual. Published by Elsevier España, S.L.  
All rights reserved.
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Resumen En este estudio se comparó la eficacia de la exposición a estímulos virtuales combi-
nada con terapia cognitivo-conductual (VRET) con un programa tradicional cognitivo-conductual 
(CBT) para reducir la sintomatología fóbica en una muestra de personas con agorafobia de larga 
evolución. Se utilizó un diseño entre sujetos con tres condiciones experimentales (grupo VRET, 
N = 30; grupo CBT, N = 30; y grupo con sólo medicación, N = 20) y medidas repetidas (pre, post-
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Anxiety disorders are a clinical problem that affects a 
considerable sector of the population. According to several 
epidemiological studies conducted according to the WHO 
criteria (e.g., ESEMeD, 2004, in six European countries), 
these disorders have a lifetime and past-year prevalence of 
about 15% and 6%, respectively. Anxiety disorders affect 
mostly women, who represent about 75% of patients. One 
of these disorders is agoraphobia, the most complex and 
disabling phobia in the phobia spectrum. 
Today, effective therapeutic resources are available for 
the treatment of agoraphobia. Among psychiatric drugs, a 
number of antidepressant medications have shown efficacy 
regarding symptom remission. Specifically, paroxetine and 
venlafaxine have proven to be highly effective and 
tolerable by patients (Farach et al., 2012; Mochcovitch & 
Nardi, 2010). Cognitive-behavioral therapy (CBT) is 
available as a psychological treatment package for 
agoraphobia. The efficacy of CBT can increase when 
gradual exposure to phobic stimuli is included in the 
program (Baker, Patterson, & Barlow, 2002; Culver, 
Stoyanova, & Craske, 2012).
There are different types of exposure. In vivo exposure 
therapy seems to be the most effective type (Wiederhold & 
Rizzo, 2005). However, many patients are reluctant to 
confront real stimuli. In this regard, virtual reality (VR) 
stimuli can play an intermediate role; instead of being 
directly confronted with real stimuli, patients are 
confronted with their virtual counterpart (Shiban, Pauli, & 
Mühlberger, 2013). Virtual reality exposure treatment 
(VRET) is a procedure that is similar to CBT but uses VR 
(usually combined with in vivo stimuli) to expose patients 
to feared stimuli. Both traditional CBT exposure and VRET 
are based on the model of emotional processing of fear 
(Abramowitz, Deacon, & Whiteside, 2011; Foa, Huppert, & 
Cahill, 2006; Neudeck & Wittchen, 2012; Reinecke, Rinck, 
Becker, & Hoyer, 2013), although the underlying processes 
still remain controversial (e.g., Kämpfe et al., 2012).
Several reviews about anxiety treatment (i.e., de 
Carvalho, Freire, & Nardi, 2010; Krijn, Emmelkamp, 
Olafsson, & Biemond, 2004; Opriş et al., 2012; Peñate, 
2012; Powers & Emmelkamp, 2008) have shown that VRET 
appears to be more effective than in-imagination exposure; 
in fact, VRET seems to yield similar results to in vivo 
exposure as long as the ‘sensation of presence’ (i.e., the 
feeling of being inside the virtual environment) is guaranteed 
(Alsina-Jurnet, Gutiérrez-Maldonado, & Rangel-Gómez, 
2011). Specific data on agoraphobia are less conclusive: 
Meyerbroeker, Morina, Kerkhof, and Emmelkamp (2013) 
found that traditional CBT with in vivo exposure led to 
better results than VRET. Yet, Botella et al. (2007), 
Gonzalez-Lorenzo et al. (2011), and Pitti et al. (2008) found 
that VRET was able to yield similar (or better) results than 
CBT, especially when combined with in vivo exposure. This 
combination was found to obtain better results than VRET 
alone (Malbos, Rapee, & Kavakli, 2013).
As pointed out by de Carvalho et al. (2010), VRET has 
some advantages because it overcomes some limitations of 
in vivo techniques. This is especially true with long-term 
agoraphobia. Patients with chronic agoraphobia tend to 
have high dropout rates, be reluctant to new exposure, and 
overuse benzodiazepines. They often have a history of 
unsuccessful in vivo exposure and experience panic attacks 
and therefore do not adhere to new exposure treatment or 
drop out during its application. VRET can appear as an 
attractive and safe resource for such patients. VR stimuli 
can play an intermediate role, increase confidence in the 
technique and patient compliance, and reduce dropout 
rates.
In the context of cognitive-behavioral therapies, the aim 
of this study was to assess the efficacy of VRET in multiple 
context exposure (Balooch & Neumann, 2011; Shiban et al., 
2013) combined with in vivo exposure as a therapeutic 
program to improve treatment compliance and reduce 
dropout rates in patients with long-term agoraphobia (i.e., 
more than 5 years of evolution of the disorder). We intended 
to compare the efficacy of the above-mentioned treatment 
with that of traditional exposure therapy (CBT), and 
antidepressants alone.
It should be noted that long-term agoraphobia patients 
are medicated (or self-medicated) with a number of 
different psychodrugs. They are resistant to discontinue 
medication because they consider it necessary to prevent 
anxiety attacks. To control the role of psychodrugs in the 
final results and increase sample homogeneity, researchers 
ensured that patients used the same group of antidepressants 
(i.e., paroxetine and venlafaxine) as the most efficient 
drugs to control agoraphobia symptoms (i.e., Farach et al., 
2012).
Our main hypothesis was that combined VRET + in vivo 
exposure would lead to similar statistical and clinical 
improvements as traditional exposure therapy (CBT) and 
better results than medication alone, but VRET would 
achieve better treatment compliance and lower dropout 
rates.
Antidepresivos; 
Estudio experimental
tratamiento y seguimiento a los seis meses). Todos los pacientes estaban tomando antidepresi-
vos. Los resultados mostraron que todas las terapias fueron estadísticamente eficaces, tanto en 
el post-tratamiento como en el seguimiento. El grupo VRET mostró mayores mejoras clínicas 
en el seguimiento. El grupo CBT mostró las tasas más altas de abandono. VRET probablemente 
juega un papel intermedio para una exposición eficiente a los estímulos fóbicos. Más allá de las 
ventajas de un procedimiento VRET para el tratamiento de la agorafobia en términos de coste-
beneficios, este estudio también destaca los posibles beneficios en la mejora en la motivación 
y adherencia al tratamiento.
© 2013 Asociación Española de Psicología Conductual. Publicado por Elsevier España, S.L.  
Todos los derechos reservados.
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Method
Participants
Patients were referred from mental health units of the 
Psychiatric Service of the Canary Islands University 
Hospital, in Spain, where the study was conducted from 
September 2011 to July 2012. Inclusion criteria for 
participants were meeting the criteria of the DSM-IV-TR 
(American Psychiatric Association [APA], 2000) and ICD-10 
(World Health Organization [WHO], 1992) for the diagnosis 
of agoraphobia (with or without panic disorder). Exclusion 
criteria were having a diagnosis of psychosis, personality 
disorders, or other anxiety disorders with agoraphobia 
disorder as a secondary diagnosis. All participants signed 
a consent form approved by the institutional ethics 
committee of the Canary Islands University Hospital. Once 
admitted, patients were assigned to three treatment 
groups according to a previously generated table of 
random numbers, indicating which numbers belonged to 
each group.
From an initial sample of 80 patients, 50 patients with 
five or more years of evolution of agoraphobia (with and 
without panic attacks) completed the entire treatment 
phase. Dropout rates are described in the Results section. 
Intention-to-treat analyses were conducted using the last-
observation-carried-forward method.
Of the the 50 participants who completed the treatment, 
11 had been diagnosed with agoraphobia without panic 
disorder and 39 had been diagnosed with agoraphobia with 
panic disorder. The age range was 24 to 60 years. Most 
participants in the sample were women (72%). Regarding 
marital status, 48% were married, 40% were single, and 12% 
were separated or divorced. Evolution time of clinical 
symptoms ranged from 5 to 30 years, with a mean evolution 
time of 11.46 years (SD = 6.1). 
A single therapist applied both CBT in vivo exposure 
treatment and VRET. The therapist was a clinical psychologist 
with more than 15 years’ experience as a practitioner.
Material and apparatus
The following measuring instruments were administered to 
assess and verify the diagnosis of agoraphobia: 
-  Composite International Diagnostic Interview (CIDI), 2.1. 
It is a structured interview designed to assess mental 
disorders according to the criteria established by the ICD-
10 (Kessler & Üstün, 2004; WHO, 1992). Only the questions 
about phobias and panic were used.
-  Agoraphobia Inventory (AI). The AI (Echeburúa, Corral, 
García, Páez, & Borda, 1992) measures general level of 
agoraphobia using 69 items structured into two sections. 
The first part measures different types of altered responses 
of patients alone and in company when faced with the 
most common stimuli associated to agoraphobic situations. 
The second part examines response variations as a function 
of factors that contribute to increasing and decreasing 
anxiety. For the purposes of this study, it was interesting 
to obtain separate scores for patients’ responses when 
alone and in company, as two subscales (AI-accompanied 
and AI-alone). The authors (Echeburúa et al., 1992) 
describe appropriate psychometric properties for 
agoraphobia severity and for the selection of target 
behaviors in agoraphobia disorders.
The following questionnaires and scales were administered 
to measure clinical symptoms and therapeutic progress 
(outcome measures):
-  Agoraphobic Cognition Questionnaire (ACQ). The ACQ 
(Chambless, Caputo, Bright, & Gallagher, 1984) assesses 
catastrophic thoughts that occur when experiencing 
anxiety on a 5-point Likert scale. The authors have 
reported a final adequate internal consistency (α = .80), 
high test-retest stability (r = .86), and final one-factor 
solution. Also, the total score discriminates between 
patients with agoraphobia and a normal control sample.
-  Body Sensations Questionnaire (BSQ). The BSQ (Chambless 
et al., 1984) is a self-report questionnaire composed of 
17 items about physical sensations when experiencing 
anxiety, rated on a 5-point Likert scale. Again, the authors 
have reported high internal consistency (α = .87), 
moderate test-retest stability (r = .67), and the scale 
discriminate between patients with agoraphobia and a 
normal control sample.
-  Beck Anxiety Inventory (BAI). The BAI (Beck, Epstein, 
Brown, & Steer, 1988) is a self-report instrument that 
measures the severity of anxiety in adults and adolescents 
using 21 multiple-choice items. Responses are provided 
on a 4-point scale. Beck et al. (1988) reported high 
internal consistency (α = .92), an adequate one-week 
test-retest stability (r = .75), and discriminant validity in 
describing different anxiety levels.
-  Liebowitz Social Anxiety Scale (LSAS). The LSAS (Liebowitz, 
1987) is a Likert scale designed to assess the severity of 
social anxiety disorder. The scale is composed of 24 items 
assessed from two approaches: 1) fear experienced by 
the patient in such situations (LSAS-fear), and 2) degree 
of avoidance of them (LSAS-avoidance). Scales have 
obtained high α coefficients (.92 for LSAS-fear; .92 for 
LSAS-avoidance; and .96 for total score), and adequate 
treatment sensitivity, with the following effect sizes: .65 
for LSAS-fear; .67 for LSAS-avoidance; and .67 for total 
score (Heimberg et al., 1999).
-  0±58 to 0±67 Subjective Units of Anxiety (SUA). With this 
instrument, patients rate their degree of anxiety regarding 
phobic stimuli from 0 to 10. These measures were taken 
at the end of all sessions.
-  Behavioral Avoidance Test (BAT). At the end of the 
program, patients were encouraged to cope with two real 
scenarios that were similar to the virtual environments. 
Patients were accompanied by a therapist helper. The 
task involved walking in those environments for a 
maximum of 20 minutes. Patients were informed that if 
they felt anxious they could return to the place where the 
helper was waiting and that they could also refuse to 
perform the task. Time (i.e., minutes on the street) and 
SUA measures were taken.
The Virtual Reality System and the software used in 
this study were the same as those used in the study by 
Peñate, Pitti, Bethencourt, de la Fuente, and Gracia 
(2008). The virtual environments were seven possible 
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phobic stimuli for agoraphobia patients: an airport 
building and a plane, a square and a street, an elevator 
and an underground car park, a bank office, a highway, 
a beach, and a cableway.
Design
A randomized clinical trial was designed. As pointed out in 
the Participants section, patients were selected by their 
psychiatrist or psychologist (i.e., non-random selection). 
Next, they were randomly assigned to one of the three 
groups according to a previous random number assignation. 
Based on the independent variables, we used a factorial 
between-subject experimental design with repeated 
measures (Montero & León, 2007). The design included two 
independent variables and one covariate (drug). The 
first independent variable was type of treatment (three 
levels). The second independent variable was time lapse 
between the different measuring times (three levels). 
Thus, the design considered three types of treatment 
(between-subject factor): CBT + drug, hereinafter referred 
to as CBT (initial N = 30; 23 paroxetine, 7 venlafaxine); VR 
+ CBT + drug, hereinafter VRET (initial N = 30; 20 paroxetine, 
10 venlafaxine); and a group of patients on the waiting list 
for psychological treatment + drug, hereinafter DRUG 
(initial N = 20; 15 paroxetine, 5 venlafaxine). In the CBT 
and VRET groups, measures (within-subject factor) were 
taken at three levels: pre-treatment, post-treatment, and 
6-month follow-up. In the DRUG group, measures were 
taken at pre-treatment and post-treatment. At the end of 
this stage, free psychological treatment was provided to 
those who requested it. This group included only 20 patients 
(instead of 30 as in the other two groups) because the aim 
was just to have enough participants for statistical tests, 
considering, as previous studies had revealed, that this 
group would show the least improvement.
The following measures were used as dependent variables: 
cognitive and overt behaviors related to agoraphobia when 
the patient was alone (AI-alone) and when the patient was 
accompanied (AI-accompanied), agoraphobic cognitions 
(ACQ), physiological reactivity (BSQ), general anxiety (BAI), 
social anxiety: fear of situations (LSAS-fear) and avoidance 
of these social situations (LSAS-avoidance), and self-
perceived anxiety (SUA).
Procedure
After an initial screening, a clinical psychologist confirmed 
the diagnosis with the CIDI 2.1 interview and the AI. 
Patients who accepted to participate gave written 
informed consent and completed the pre-treatment 
measures. All patients had a clinical course of at least 
5 years with a diagnosis of agoraphobia disorder. All 
participants were taking psychodrugs (paroxetine or 
venlafaxine) and received a dose between 20 and 30 mg/
day or between 37.5 and 75 mg/day, respectively, 
according to psychiatric prescription.1 They were randomly 
assigned to the different combination therapy groups (CBT 
or VRET) or to the DRUG group.
Each experimental group received 11 individual clinical 
sessions that lasted 30-45 minutes each. The first three 
sessions were similar in both treatment groups. They 
consisted of a psycho-educational session and two training 
sessions in cognitive restructuring. Patients in the CBT 
group were encouraged to confront phobic environments 
with in vivo exposure. Patients in the VRET group received 
a combination of in vivo exposure and VR exposure sessions. 
They were exposed to the four virtual environments that 
had caused most anxiety in them. Subjective Units of 
Anxiety (SUA) measurements were taken at the end of all 
sessions. Once the psychotherapy sessions had ended, the 
post-treatment measures were taken. Six months later, 
patients attended a psychological and psychiatric follow-up 
session and completed the follow-up measures.2
Data analysis
Several tests were performed. First, an analysis was carried 
out to verify whether the dropout rate was significant in 
terms of group membership. Next, the three experimental 
groups were subjected to a pre-test/post-test repeated-
measures analysis of covariance (MANCOVA) of each of the 
variables of the clinical symptoms, with the drug as a 
covariate. 
Later, a pre-test, post-test, and follow-up repeated-
measures MANCOVA was performed again with the two 
treatment groups (CBT and VRET), using type of drug 
(paroxetine or venlafaxine) as a covariate.
A repeated-measures analysis of variance with eight 
levels (seven psychotherapy sessions and one follow-up 
session) was conducted on the Subjective Units of Anxiety 
(SUA) to determine if the level of anxiety was the same at 
the three points in time measured and whether there was 
a significant interaction between the time each of the 
measures was taken and treatment. 
Finally, an analysis was performed to distinguish the 
degree of acquiescence to participate in the behavioral 
avoidance test (BAT) for each treatment type. Another goal 
was to determine the level of subjective anxiety felt by 
patients in each of the two scenarios they were exposed to 
and the average exposure time.
Results
As previously anticipated, dropouts were considered first. 
Figure 1 represents the flowchart of the sample from pre-
treatment to follow-up. As can be observed, there were 
considerable dropout rates. Out of the 80 patients who 
were assigned to different groups, 37.5% left the study 
during treatment; most of them (more than 50%) belonged 
to the CBT group. The VRET group had the lowest dropout 
rates. Most dropouts (N = 15) took place at the beginning 
of treatment (before the exposure sessions). The main 
1. To increase the homogeneity of the sample, given that all 
patients were taking drugs, participants were encouraged to 
change their medication for the best tested medicines: paroxetine 
or venlafaxine. The last author, a psychiatrist, prescribed the 
antidepressant and its dosage according to each patient’s clinical 
history.
2. Additional information about the program can be provided by 
the corresponding author.
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reasons were lack of novelty compared to previous 
treatments and schedule problems. Seven patients left the 
program when the in vivo exposure sessions began (Session 
4). They considered that the task made them suffer. It was 
not possible to find out the reasons why another 12 patients 
left. A comparison with pre-treatment rates showed 
significant differences (χ2(2) = 5.83; p = .05). Dropout rates 
increased at follow-up and, again, the group with the 
highest rates was the CBT group; yet, no significant 
differences were found at this stage (χ2(1) = 1.76).
Next, a repeated-measures MANCOVA was performed 
with two factors: time (two levels: pre-treatment and post-
treatment) and treatment (CBT, DRUG, and VRET), with 
drugs as a covariate. Table 1 shows the mean and standard 
deviation of the different conditions for each outcome 
measure at post-treatment and six-month follow-up. 
Significant differences were found in the treatment x time 
interaction (Wilks’ Lambda = .42, F = 1.93, p = .02, η2 = 
.34). Results showed a significant effect of treatment on 
the variable measuring agoraphobic cognitions (ACQ), F(2, 41) 
= 5.21 (p = .01, η2 = .20), body sensations (BSQ), F(2, 41) = 
5.63 (p = .00, η2 = .21), general anxiety (BAI) F(2, 41) = 3.45 
(p = .04, η2 = .14), cognitive and overt behaviors related to 
agoraphobia when the patient was alone (IA-alone), F(2, 41) = 
5.15 (p = .01, η2 = .20), and cognitive and overt behaviors 
related to agoraphobia when the patient was accompanied 
(AI-accompanied) F(2, 41) = 4.96 (p = .01, η2 = .19). Results 
show that both the CBT and VRET group obtained better 
scores on these variables compared to the DRUG group.
Another repeated-measures MANCOVA was performed 
with two factors: time (three levels: pre-treatment, post-
treatment, and follow-up) and treatment (CBT and VRET, 
because there was no follow-up of the DRUG group). No 
significant differences were found in the multivariate 
analysis. In the univariate analysis, results showed that 
there was only a significant effect of treatment on the 
variable measuring cognitive and overt behaviors related to 
agoraphobia when the patient was alone (IA-alone), F(2, 40) = 
3.97 (p = .27, η2 = .16), where patients in the VRET group 
showed greater improvement.
To test the changes in Subjective Units of Anxiety (SUA), 
a repeated-measures analysis of variance (ANOVA) was 
carried out to analyze session-to-session effects. We 
analyzed the effects from Session 5 (when exposure was 
activated) to follow-up. Although the results showed a 
significant time effect, F(4.03, 92.82) = 3.21, p = .01, η2 = .12, 
the treatment x time interaction was not significant: all 
the treatments reduced SUA scores but no differences were 
found between them.
For the BAT procedure, patients were exposed to the 
following scenarios: “car park and elevator” (scenario 1) 
and “square and street” (scenario 2). Fourteen patients 
CBT
 n = 30
VRET
n = 30
DRUG
n = 20
Post-treatment
n = 50
dropout: 37.5%
CBT
n = 14
dropout: 53.33%
VRET
n = 23
dropout: 23.33%
DRUG
n = 13
dropout: 353%
Follow-up
n = 23
dropout: 71.25%
CBT
n = 9
dropout: 70%
VRET
n = 14
dropout: 53.33%
Initial sample
n = 80
Figure 1 Flowchart representing sample assignment, sample sizes, and dropout rates (from the initial sample) at the three 
moments of assessment. 
Note. 
CBT = cognitive-behavioral treatment; VRET = virtual exposure treatment.
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were assigned to the combination therapy groups (seven to 
the CBT group and seven to the VRET group). Four patients 
in the CBT group (and one in the VRET group) refused to 
take part in BAT exposure. Table 2 shows the mean time 
spent in each scenario and the level of perceived anxiety 
(SUA). It should be noted that the VRET group had lower 
self-perceived anxiety scores in both scenarios. According 
to Mann-Whitney’s U coefficient, a statistical difference 
was found in time spent in Scenario 1 (U = 0.00; p = .02). 
This result showed that VRET patients spent more time 
than CBT patients did. No other statistical differences were 
found.
Overall, results failed to show statistical differences 
between the combination therapy groups in the outcome 
measures; however, the average scores on those clinical 
variables showed a greater decrease in some groups than 
others (Table 1). This differential decrease led us to 
consider if there were clinical differences between the 
experimental groups.
According to the data shown on Table 1, clinical 
improvement was considered to occur when the scores of 
variables decreased by 50% compared to pre-treatment 
scores (pre-treatment scores minus post-treatment scores, 
and pre-treatment scores minus six-month follow-up 
scores). Neither group showed a 50% decrease in ACQ and 
BSQ scores. By contrast, the VRET group showed a 50% 
decrease at follow-up in the rest of variables (i.e., AI-alone, 
AI-accompanied, LSAS-fear, LSAS-avoidance), whereas the 
CBT group only showed this decrease at post-treatment in 
general anxiety (BAI). When this analysis was performed 
with the group treated only with drugs, as shown on 
Table 1, none of the scores decreased by 50% between pre-
treatment and post-treatment; instead, some scores of this 
group showed a slight increase at post-treatment.
Table 1 Mean and standard deviation of the outcome measures at pre-treatment, post-treatment, and follow-up.
 CBT VRET DRUG
 n (post-) = 14 n (post-) = 23 n (post-) = 13
 n (follow-up) = 9 n (follow-up) = 14 
 M (SD) M (SD) M (SD)
ACQ   
Pre-treatment 38.07 (9.46) 37.30 (7.63) 32.30 (9.46)
Post-treatment 25.50 (8.67) 28.72 (7.28) 30.15 (8.33)
Follow-up 28.00 (10.90) 24.57 (9.27) 
BSQ   
Pre-treatment 58.35 (9.94) 57.17 (12.79) 54.46 (11.78)
Post-treatment 39.57 (9.78) 46.27 (9.41) 50.84 (11.28)
Follow-up 45.66 (14.71) 39.07 (11.04) 
BAI   
Pre-treatment 32.57 (13.42) 30.47 (11.83) 31.38 (12.65)
Post-treatment 14.78 (9.93) 16.83 (11.52) 27.07 (13.33)
Follow-up 17.33 (8.73) 16.22 (16.64) 
AI-alone   
Pre-treatment 94.28 (47.48) 98.50 (32.39) 83.65 (33.39)
Post-treatment 69.23 (42.60) 69.23 (42.60) 96.33 (43.45)
Follow-up 77.16 (37.61) 27.92 (16.89) 
AI-accompanied   
Pre-treatment 65.07 (27.07) 70.13 (34.82) 57.15 (21.57)
Post-treatment 41.00 (38.65) 49.83 (30.19) 68.00 (26.63)
Follow-up 37.28 (21.70) 27.23 (15.54) 
LSAS-fear   
Pre-treatment 31.96 (16.52) 34.56 (19.29) 30.98 (15.77)
Post-treatment 20.76 (15.53) 28.38 (14.39) 33.33 (18.40)
Follow-up 25.71 (16.43) 16.50 (11.81) 
LSAS-avoidance   
Pre-treatment 27.59 (16.15) 31.34 (18.81) 31.31 (16.98)
Post-treatment 19.68 (16.79) 25.57 (15.34) 32.00 (20.13)
Follow-up 26.50 (16.66) 14.09 (11.49) 
Note. CBT = cognitive-behavioral treatment; VRET = virtual exposure treatment; SD = standard deviation; ACQ: Agoraphobic Cognition 
Questionnaire; BSQ = Body Sensations Questionnaire; BAI = Beck Anxiety Inventory; AI-alone = Agoraphobia Inventory (“alone” scores); 
AI-accompanied = Agoraphobia Inventory (“accompanied” scores); LSAS-fear = Liebowitz Social Anxiety Scale (feared stimuli); LSAS-
avoidance = Liebowitz Social Anxiety Scale (avoided stimuli).
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Discussion
In this study we explored the efficacy of combination 
therapy in a sample of patients with chronic agoraphobia 
(i.e., a minimum of 5 years of evolution and an average of 
11.46 years with the disorder). The aim was to test the 
efficacy of VR techniques (i.e., a virtual system based on 
7 scenarios) and compare it to traditional cognitive-
behavioral treatment regarding several clinical outcome 
measures and dropout rates. Both psychological techniques 
were combined with pharmacological treatments using 
venlafaxine and paroxetine.
First of all, dropout rates were revealing. Results showed 
that 37.5% patients abandoned the program during treatment 
sessions, and it was especially relevant for the CBT group 
(more than 50%). These data are inconsistent with those 
reported by Opriş et al. (2012), who did not found differences 
in dropout rates between traditional CBT and VRET. By 
contrast, they are consistent with rates reported by 
Meyerbroeker et al. (2013) with a sample of similar severity. 
To explain these high rates, we must consider the nature of 
the sample: patients who had had agoraphobia for at least 
five years. Over those years, these patients may have 
received several psychological or psychiatric treatments 
with poor outcomes. Thus, we consider that it is remarkable 
that only seven patients out of 30 discontinued the VRET 
treatment, showing better adherence rates. The novelty 
effect and the safety of the VRET condition may have played 
a key role in such adherence. 
According to the outcome measures, the comparison of 
the three groups at two points in time (pre-treatment and 
post-treatment) showed an improvement in different 
variables in the VRET and CBT groups compared to the 
DRUG group. Yet, when we compared the two combination 
therapy groups separately at the three points in time, 
patients treated with VR and antidepressants had lower 
scores than patients treated with CBT, but the VRET group 
showed better results in one variable. This was a relevant 
clinical variable, as it measured patients’ ability to cope 
with their anxiety when they were facing the phobic stimuli 
alone.
Overall, results showed a better adherence in the VRET 
group but no statistical differences between the CBT and 
VRET groups. Yet, the combined effects of VRET and 
antidepressants showed better levels of improvement 
regarding clinical efficacy. This study is consistent with 
those of Botella et al. (2007), Gonzalez-Lorenzo et al. 
(2011), and Pitti et al. (2008), who obtained better results 
in the combination therapy group when VR techniques were 
used. This study also has similarities with previous ones 
regarding follow-up. Gonzalez-Lorenzo et al. (2011) 
explored six-month follow-up, Peñate et al. (2008) explored 
three-month follow-up, Choi et al. (2005) assessed six-
month follow-up, and Botella et al. (2007) measured one-
year follow-up. Again, results showed greater improvement 
when VR techniques were included. 
Considering the greater clinical efficacy of VRET + 
antidepressants, we believe there are two complementary 
explanations. A first possible explanation may be that 
patients are better regulated by a process that is a good 
intermediate stage before confronting real phobic stimuli. 
VRET can play a role in the successive approximation 
process, facilitating the first contact with the feared 
stimuli. It can be an additional advantage in the treatment 
of long-term agoraphobia, because patients often have a 
history of failed in vivo exposure (Gonzalez-Lorenzo et 
al., 2011; Peñate et al., 2008). Another explanation is 
related to the mechanisms underlying VR exposure. As 
Meyerbröker and Emmelkamp (2010) pointed out in their 
review, phobic patients treated with VRET developed 
changes at cognitive level, increasing both the level of 
self-efficacy and the level of self-statements. This may 
imply that VR activates other mechanisms besides those 
proposed by the emotional processing theory (Foa et al., 
2006), which may increase its efficacy compared to 
traditional exposure technique.
The main difference between this study and previous 
research is the use of a large sample of patients diagnosed 
with chronic agoraphobia. This study included seven local 
scenarios, similarly to studies performed by Botella et al. 
(2007), Gonzalez-Lorenzo et al. (2011), and Pitti et al. (2008), 
which included various virtual scenarios, although they 
were not all local. 
It is also worth noting some limitations of this study. The 
most important one is its sample size. Although it was 
larger than in previous studies, the number of patients in 
each treatment group was never greater than 30. A relevant 
limitation is related to how results can be explained: it is 
not possible to explain the separate role of VRET or CBT 
with in vivo exposure, because the antidepressant was 
present. Therefore, results can only be interpreted as a 
function of the drug x psychological treatment interaction. 
Another limitation is the number of virtual scenarios. Even 
though the scenarios were local and therefore more 
realistic, the number of scenarios is likely to be insufficient, 
given the complexity and variability of anxiogenic situations 
for patients with agoraphobia. 
In future research, it would be interesting to study the 
psychological variables that play an important role in 
the evaluation of virtual environments and facilitate the 
Table 2 Means and sample sizes of Behavioral Avoidance Test measures.
 Scenario 1 Scenario 2
Treatment modality n Time mean SUA mean  n Time mean  SUA mean 
CBT 3 10 6 3 10 3.33
VRET  6 17.50 4.25 4 12.50 3.08
Note. SUA= Subjective Units of Anxiety; CBT = cognitive-behavioral treatment; VRET = virtual exposure treatment.
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activation of emotions during exposure. These combination 
treatments (CBT and VRET) should also be compared a 
larger samples to obtain results with greater statistical 
power. Combination therapy groups should also be compared 
with a group not receiving any psychopharmacological 
therapy. Similarly, it might be interesting to have a large 
number of VR exposure scenarios in the package of exposure 
sessions of the VR group.
In conclusion, results revealed that both combination 
therapy groups were statistically effective at post-
treatment and six-month follow-up. However, regarding 
clinical efficacy, results show the following: combination 
therapy with VRET + antidepressants seems to be better 
than traditional techniques at decreasing agoraphobic 
cognitions, depressive symptoms, measures of anxiety, and 
agoraphobic cognitions and behaviors both when patients 
are alone and when they are accompanied, as well as social 
anxiety related to fear and avoidance of these situations; 
this combination therapy also seems better at maintaining 
these improvements over time. Results also demonstrate 
that use of antidepressants such as paroxetine (an SSRI) 
and venlafaxine (an SNRI) decreases symptoms of 
agoraphobia when combined with psychological techniques, 
including exposure to virtual reality, but is not as effective 
as treatment alone. Most important, patients in the VRET 
group showed higher adherence rates. This means that this 
therapy is useful for chronic patients. These conclusions 
should be taken with caution because the final sample size 
was small and data trends did not always reach statistical 
significance.3
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